- Home
- AARD vs EIC Comparison
AARD vs EIC Comparison
Compare AARD & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AARD | EIC |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 33 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.2M | 293.8M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AARD | EIC |
|---|---|---|
| Price | $13.83 | $11.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $31.11 | $14.00 |
| AVG Volume (30 Days) | ★ 276.4K | 272.9K |
| Earning Date | 02-14-2026 | 11-13-2025 |
| Dividend Yield | N/A | ★ 13.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $59,262,402.00 |
| Revenue This Year | N/A | $37.84 |
| Revenue Next Year | N/A | $23.33 |
| P/E Ratio | ★ N/A | $10.12 |
| Revenue Growth | N/A | ★ 44.30 |
| 52 Week Low | $4.88 | $10.81 |
| 52 Week High | $19.58 | $16.39 |
Technical Indicators
Market Signals| Indicator | AARD | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 55.93 | 54.26 |
| Support Level | $12.90 | $11.35 |
| Resistance Level | $15.33 | $11.44 |
| Average True Range (ATR) | 1.19 | 0.21 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 33.96 | 93.67 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.